Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for ...

Seventy-eight FAP patients with desmoids were identified from the Dutch Polyposis Registry. Data on desmoid morphology, management, and outcome were analysed retrospectively. Progression-free survival ...

The U.S. Food and Drug Administration has approved SpringWorks Therapeutics Inc.'s Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. The ...

The treatment of desmoid tumors in patients with familial adenomatous polyposis (FAP) is controversial. Surgery has been recommended for abdominal-wall tumors, but has previously been avoided in ...

Mrinal M. Gounder, MD, a sarcoma oncologist at Memorial Sloan Kettering Cancer Center and lead investigator of the phase 3 DeFi trial of nirogacestat in desmoid tumors, discusses the drug's recent FDA ...

Pelvic desmoid fibromatosis is a rare locally aggressive benign neoplasm, typically presenting in the reproductive age group with lower abdominal pain. Extra-abdominal occurrence being predominant, ...

During a recent AJMC Peer Exchange, a panel of experts delved into the clinical characteristics and heterogeneity of desmoid tumors, the importance of a multidisciplinary approach in both ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

Desmoid tumors are rare growths that form in connective tissues, such as tendons and ligaments. Although they can affect anyone, they are more common in women. Desmoid tumors are not cancer, but they ...

This trial tried to find out how well radiotherapy worked as a treatment for desmoid tumours. Desmoid tumours are also sometimes called aggressive fibromatosis. This rare tumour grows in fibrous ...

Ogsiveo is the first and only drug approved by the FDA to treat desmoid tumors. The FDA has approved nirogacestat (Ogsiveo) for adults with progressing desmoid tumors requiring systemic treatment. 1,2 ...